Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Super P-Force is an oral combination therapy developed and manufactured by Sunrise Remedies for the treatment of erectile dysfunction and premature ejaculation. It contains sildenafil citrate, a phosphodiesterase type 5 (PDE5) inhibitor, and dapoxetine hydrochloride, a selective serotonin reuptake inhibitor (SSRI). Sildenafil enhances the smooth muscle relaxant effects of nitric oxide by blocking PDE5, thereby increasing blood flow to the penis. Dapoxetine acts by inhibiting the serotonin transporter (SERT), increasing serotonin levels in the synaptic cleft and delaying the ejaculatory reflex. This dual-action approach addresses both the physical and psychological aspects of male sexual dysfunction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Super P-Force.